Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm ...

The impact of chronic kidney disease (CKD) keeps escalating around the world, and this burden is projected to rise with ...

Fish delivers protein, and when you choose a fatty fish like tuna, salmon or trout, you're also getting omega-3 fatty acids.

Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

The following is a summary of “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial,” published in the February 2025 issue of Nephrology Dialysis ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and management of chronic kidney disease (CKD) in adults and children.

Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.